Division of Newborn Medicine, Department of Pediatrics, Boston Children's Hospital, Boston, MA; Division of Genetics and Genomics, Department of Pediatrics, Boston Children's Hospital, Boston, MA; Department of Pediatrics, Harvard Medical School, Boston, MA.
Division of Newborn Medicine, Department of Pediatrics, Boston Children's Hospital, Boston, MA; Division of Genetics and Genomics, Department of Pediatrics, Boston Children's Hospital, Boston, MA; Department of Pediatrics, Harvard Medical School, Boston, MA; The Manton Center for Orphan Disease Research, Boston Children's Hospital, Boston, MA.
Genet Med. 2024 Sep;26(9):101177. doi: 10.1016/j.gim.2024.101177. Epub 2024 Jun 6.
Critically ill infants from marginalized populations disproportionately receive care in neonatal intensive care units (NICUs) that lack access to state-of-the-art genomic care, leading to inequitable outcomes. We sought provider perspectives to inform our implementation study (VIGOR) providing rapid genomic sequencing within these settings.
We conducted semistructured focus groups with neonatal and genetics providers at 6 NICUs at safety-net hospitals, informed by the Promoting Action on Research Implementation in Health Services framework, which incorporates evidence, context, and facilitation domains. We iteratively developed codes and themes until thematic saturation was reached.
Regarding evidence, providers felt that genetic testing benefits infants and families. Regarding context, the major barriers identified to genomic care were genetic testing cost, lack of genetics expertise for disclosure and follow-up, and navigating the complexity of selecting and ordering genetic tests. Providers had negative feelings about the current status quo and inequity in genomic care across NICUs. Regarding facilitation, providers felt that a virtual support model such as VIGOR would address major barriers and foster family-centered care and collaboration.
NICU providers at safety-net hospitals believe that access to state-of-the-art genomic care is critical for optimizing infant outcomes; yet, substantial barriers exist that the VIGOR study may address.
处于边缘地位的危重症婴儿在新生儿重症监护病房(NICU)接受治疗,而这些 NICU 缺乏获得最先进基因组护理的途径,导致结果不公平。我们寻求提供者的观点,以为我们在这些环境中提供快速基因组测序的实施研究(VIGOR)提供信息。
我们在 6 家安全网医院的 NICU 中与新生儿和遗传提供者进行了半结构化焦点小组讨论,该研究以促进卫生服务研究实施行动框架为指导,该框架结合了证据、背景和促进领域。我们不断开发代码和主题,直到达到主题饱和。
关于证据,提供者认为基因检测有益于婴儿和家庭。关于背景,确定的基因组护理主要障碍是基因检测成本、缺乏遗传咨询和随访方面的专业知识,以及在选择和订购基因检测方面的复杂性。提供者对 NICU 中当前的基因组护理现状和不公平性感到不满。关于促进,提供者认为 VIGOR 等虚拟支持模式可以解决主要障碍,并促进以家庭为中心的护理和合作。
安全网医院的 NICU 提供者认为,获得最先进的基因组护理对于优化婴儿的结果至关重要;然而,仍然存在重大障碍,VIGOR 研究可能会解决这些障碍。